Back to results
US 7,622,119 B2Granted
Cancer antigen peptides derived from WT1
AssigneeInternational Institute of Cancer Immunology, Inc.
InventorHaruo Sugiyama
Life of this patent
Estimating the term…
Abstract
The present invention relates to HLA-A26-binding cancer antigen peptides derived from WT1, polynucleotides encoding such a peptide, CTL-inducers, and cancer vaccines comprising such a peptide or polynucleotide.
Claims10
A method for inducing CTL that specifically recognize a complex of an HLA-A26 antigen and a peptide as set forth in any one of SEQ ID NOs:
- 2, 8 and 9, which comprises contacting peripheral blood mononuclear cells from an HLA-A26 positive subject with said peptide.
Dependencies are inferred from the claim text.